摘要
目的动态观察α-干扰素联合胸腺肽治疗慢性乙型肝炎(CHB)过程中患者外周血IL-12水平,观察CHB患者对干扰素联合胸腺肽治疗的反应及免疫状态。方法 100例患者随机分为α-干扰素联合胸腺肽组和α-干扰素组,采用ELISA方法及PCR方法检测各组IL-12和HBV-DNA含量,同时观察各组ALT水平的变化。结果治疗结束时联合组与干扰素组比较,IL-12水平明显增加(P<0.05),联合组血清HBVDNA阴转率及ALT复常率指标也均优于干扰素组,且治疗结束后仍维持较长时间。结论 IL-12参与CHB的发病机制,并可作为评估干扰素联合胸腺肽抗病毒治疗的重要免疫指标。胸腺肽联合干扰素治疗CHB比单独使用干扰素疗效更好、更持久。
Objective To observe the level of IL-12 of chronic hepatitis B（CHB） patients during the treatment with interferon αcombination with thymus peptide to forecast the therapeutic effect and the immune state.Methods 100 CHB patients were stochastically divided into interferon union thymus peptide and interferon groups.The level of IL-12 was tested by ELISA and the content of HBV-DNA was tested by PCR.Results At the end of treatment,the level of IL-12 of interferon union thymus peptide group was increased than that of interferon group （P 〈0.05）,the negative rate of HBV DNA and ALT were higher in interferon union thymus peptide group than that of interferon group （P〈 0.05） and after treatment it still maintained for a long time.Conclusions IL-12 participates in the pathogenesis of CHB,and may takes an important indicator of assessing the anti-virus therapeutic effect of interferon combination with thymus peptide.The effect of thymus peptide combination with interferon for CHB is better and more lasting than the treatment of interferon.
出处
《中国老年学杂志》
CAS
CSCD
北大核心
2010年第11期1491-1492,共2页
Chinese Journal of Gerontology
基金
吉林省科技发展计划项目(20070425
200705368)
